Q2 EPS Estimate for Nektar Therapeutics Raised by Analyst

Nektar Therapeutics (NASDAQ:NKTR) – Analysts at HC Wainwright boosted their Q2 2025 earnings per share estimates for shares of Nektar Therapeutics in a research report issued to clients and investors on Tuesday, June 24th. HC Wainwright analyst A. He now expects that the biopharmaceutical company will earn ($2.68) per share for the quarter, up from their prior estimate of ($2.70). HC Wainwright currently has a “Buy” rating and a $120.00 price objective on the stock. The consensus estimate for Nektar Therapeutics’ current full-year earnings is ($0.72) per share. HC Wainwright also issued estimates for Nektar Therapeutics’ Q3 2025 earnings at ($2.58) EPS, Q4 2025 earnings at ($2.62) EPS, FY2025 earnings at ($11.49) EPS, Q2 2026 earnings at ($3.38) EPS, Q4 2026 earnings at ($3.17) EPS, FY2027 earnings at ($12.17) EPS, FY2028 earnings at ($13.98) EPS and FY2029 earnings at ($7.24) EPS.

Nektar Therapeutics (NASDAQ:NKTR) last released its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported ($3.30) EPS for the quarter, missing the consensus estimate of ($2.70) by ($0.60). The firm had revenue of $10.46 million for the quarter, compared to the consensus estimate of $15.61 million. Nektar Therapeutics had a negative net margin of 152.49% and a negative return on equity of 329.54%. During the same quarter in the prior year, the firm earned ($2.70) EPS.

NKTR has been the subject of a number of other reports. Jefferies Financial Group upgraded shares of Nektar Therapeutics from a “hold” rating to a “buy” rating and lifted their price objective for the company from $15.00 to $30.00 in a report on Friday, April 11th. William Blair reiterated a “market perform” rating on shares of Nektar Therapeutics in a report on Monday, May 12th. BTIG Research lifted their price objective on shares of Nektar Therapeutics from $60.00 to $100.00 and gave the company a “buy” rating in a report on Tuesday. Wall Street Zen downgraded Nektar Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, May 14th. Finally, Oppenheimer upgraded Nektar Therapeutics from a “market perform” rating to an “outperform” rating and set a $90.00 price target for the company in a report on Friday, March 14th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Nektar Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $76.43.

Nektar Therapeutics Stock Down 13.2%

NASDAQ NKTR opened at $25.76 on Friday. The company has a market cap of $319.68 million, a price-to-earnings ratio of -2.68 and a beta of 0.55. The business has a 50 day moving average price of $11.51 and a 200-day moving average price of $12.22. Nektar Therapeutics has a 52 week low of $6.48 and a 52 week high of $37.38.

Hedge Funds Weigh In On Nektar Therapeutics

Several hedge funds have recently modified their holdings of the company. Voya Investment Management LLC lifted its position in shares of Nektar Therapeutics by 46.8% during the 1st quarter. Voya Investment Management LLC now owns 266,773 shares of the biopharmaceutical company’s stock worth $181,000 after buying an additional 85,094 shares in the last quarter. Rhumbline Advisers grew its position in shares of Nektar Therapeutics by 23.3% during the 1st quarter. Rhumbline Advisers now owns 221,761 shares of the biopharmaceutical company’s stock valued at $151,000 after acquiring an additional 41,948 shares during the period. Acadian Asset Management LLC grew its position in shares of Nektar Therapeutics by 1.4% during the 1st quarter. Acadian Asset Management LLC now owns 7,301,734 shares of the biopharmaceutical company’s stock valued at $4,961,000 after acquiring an additional 100,645 shares during the period. Fred Alger Management LLC purchased a new stake in shares of Nektar Therapeutics during the 1st quarter worth approximately $344,000. Finally, Integrated Wealth Concepts LLC bought a new stake in shares of Nektar Therapeutics in the 1st quarter worth approximately $68,000. Institutional investors own 75.88% of the company’s stock.

Nektar Therapeutics Company Profile

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.